Sponsored by

Please click on the above banner for more details

WEBSITECHANGES

You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.

Click HERE for details on RSS.

Displaying items 1676 to 1700 of about 5880

Previous 25

Website Changes

05/01/2016

05/01/2016

04/28/2016

The Musella Foundation has created a brain tumor immunotherapy fund to raise money for immunotherapies.

04/28/2016

Nate Brundage continues the fight against brain cancer

04/27/2016

NCI opens online platform to submit ideas about research for Cancer Moonshot

04/27/2016

Experimental therapy for brain cancer developed by UCLA and Caltech could prevent drug resistance

04/27/2016

Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.

04/27/2016

Research findings could lead to treatment for deadly brain cancer

04/07/2016

High cancer drug costs lead to delays in filling prescriptions, study finds

04/05/2016

MOVING THE FIELD TOWARD MORE PATIENT-FOCUSED DRUG DEVELOPMENT

04/05/2016

National Brain Tumor Society`s CEO Named to Cancer Moonshot Initiative`s Blue Ribbon Panel of Experts /h3>

04/05/2016

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

04/04/2016

Brain Cancers Reveal Novel Genetic Disruption in DNA

04/04/2016

11th SURVIVING BRAIN TUMORS AWARENESS EVENT— MAY 23 & 24, 2016—AT CLEVELAND CLINIC

03/30/2016

03/18/2016

LIVE Youtube Streaming TONIGHT! @ 5:30PM PST (8:30 PM Eastern) Patient Education Event for Brain Tumor Patients & Families

03/17/2016

Tocagen to Present at Three Oncology Conferences

03/17/2016

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

03/17/2016

Ependymoma Awareness Day

03/14/2016

March Madness Brain Cancer Fundraiser in Memory of Wilton Woman’s Sister

03/08/2016

CNY 6-year-old with aggressive cancer beating odds with `superhero` treatment

03/07/2016

Data Safety and Monitoring Board Recommends Celldex`s Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease

03/07/2016

Correction on Celldex article

03/05/2016

The Curcumin Analog C-150, Influencing NF-?B, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo.

03/04/2016

Dbait: An innovative concept to inhibit DNA repair and treat cancer

Our privacy / cookie policy has changed.
Click HERE to read it!